Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
27 January 2022 | Story Leonie Bolleurs | Photo Supplied
Director and co-producer Mpendulo Myeni believes when it comes to making it in the film industry, one should use all the resources and opportunities you have at your disposal.

A single, unemployed mother; institutional corruption, blackmail, and the powerful players behind it. These are all ingredients for a 29-minute short film, Leshano, currently available on Showmax. 

Mpendulo Myeni, director and co-producer of the production that was filmed between Bloemfontein and Bothshabelo last year, says he was initially attracted to the script by writer and executive producer, Anton Fisher (a former Director of Strategic Communications at the UFS). “Hearing his creative ideas, I fell deeper into the storyline, wanting to explore the story and tell it with my own voice.”

Besides Myeni’s involvement with Leshano (The Lie), which was filmed in Sesotho with English subtitles, a number of other Free State artists contributed to the film. Napo Masheane, who grew up in Qwaqwa, was cast in the lead role. He is supported by Maria de Koker, Vincent Tsoametsi, Seipati Mpotoane, Pesa Pheko, Ntsiki Ndzume, and Shayne Nketsi. 

Aspiring filmmakers in the province also had the opportunity to be part of this success story, whether as make-up artists, wardrobe assistants, or location scouts. 

Myeni says Bloemfontein artists and spectators are excited to see that a film shot locally has been accepted by the streaming service, Showmax. “The story has been welcomed and has had an overwhelming response on social media by the Free State audiences. Dignitaries in the Free State Provincial Department of Sports, Arts, Culture and Recreation also positively commented on social media.”

“The Free State audience has embraced our creative expression. Many have requested for the story to be turned into a series,” he says.

Creative at heart

Myeni, a creative at heart, studied Drama and Theatre Arts, as well as Film and Visual Media up to honours level at the UFS. He also had the opportunity to study as exchange student at the University of Groningen in their film master's programme.

The international experience ignited his passion for filming and got him fired up and ready to create. He was involved in the production of several films. “I co-wrote and directed Eyelash (2020), which won a jury award, iamAFRICA, at the Pan African Film Festival in Los Angeles. This led me to create the critically acclaimed lockdown film, called Let Me Out. This film was praised by notable film critic Robyn Sassen as ‘a coronavirus gem’, like Vincent Mantsoe’s dance piece, Cut … to materialise on the cultural sphere, and it deserves as much attention as it can garner.” Another recent creation from Myeni is Amanzi, a short film yet to be released. “I also directed The Lie and collaborated with amazing creatives during the venture,” he elaborates. 

The complete Eyelash experience, winning the iamAFRICA award at the Pan African Film Festival in Los Angeles, might have been one of those life-changing moments for Myeni. He confirms: “Going to America was definitely an out-of-this-world experience, especially being such a big accomplishment – winning an internationally recognised film award from a distinguished film festival. I also got to meet and talk to the director of YouTube originals, as well as other filmmaking creatives.”

Firm foundations

Besides being an UFS alumnus and award-winning filmmaker, Myeni, who on a previous occasion received the Richard Miles award in the Faculty of the Humanities, is now working as an assistant officer in the Department of Architecture at the UFS. “I largely work with research and the creative outputs of postgraduate students. Furthermore, I manage the research hub and library and I also run the visual media aspect within the department.”

In addition, Myeni is also completing his master’s degree in Film and Visual Media at the university. “The academia and higher learning are very important to me; you can say that I am motivated by the academic avenues and learning opportunities that my position affords me,” he says. 

He believes that any lived experience will give insight into your character and abilities. “This experience in the film industry will carry me through to give more of myself in my current position, both academically and creatively.”

“I will never stop creating; my future holds more films, with me involved in producing and directing them.” In five years’ time, I see myself having been the creator of at least three other short films, and one feature film,” concludes Myeni.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept